Biotech clinical trials demonstrated that pairing GLP-1 receptor agonists with monoclonal antibodies inhibiting myostatin (bimagrumab/trevogrumab) produces dramatic body composition shifts: patients lost 25% of body fat while simultaneously gaining lean skeletal muscle mass, overcoming the primary sarcopenic side-effect of modern anti-obesity therapies. nextbigfuture.com